---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-910"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-910. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Statistical analysis description, and 1 further heading. 11 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-910"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-910

<a id="heading-3.1.10"></a>

## 3.1.10 ABX464-910

<a id="heading-3.1.10.1"></a>

### 3.1.10.1 Objective

<a id="topic-3.1.10.1-1"></a>

#### Purpose stated in the EU register title

> “A study to investigate the effects of multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone) in healthy female participants of childbearing potential.”

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00)

<a id="heading-3.1.10.2"></a>

### 3.1.10.2 Location and Study Date

<a id="topic-3.1.10.2-1"></a>

#### Trial dates and status in the EU register

| Field | Register entry |
| --- | --- |
| Protocol code | “Protocol code: ABX464-910” |
| Location | “Locations Belgium” |
| Start of trial | “Start of trial 10/10/2023” |
| End of trial | “End of trial 31/08/2024” |

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00)

<a id="topic-3.1.10.2-2"></a>

#### Trial site

> “Advanced Technology Corporation”
> “ATC, Avenue Hippocrate 15, 4000, Liege”

Source: [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00)

<a id="heading-3.1.10.3"></a>

### 3.1.10.3 Study Design

<a id="topic-3.1.10.3-1"></a>

#### Phase 1 drug-drug interaction design

> “Trial Phase Human Pharmacology (Phase I)- Other”

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00)

<a id="topic-3.1.10.3-2"></a>

#### Drug-drug interaction trials described in the Form 20-F

> “two drug-drug interaction trials, for the purposes of providing further information on any possible interactions of obefazimod with other drugs”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.10.4"></a>

### 3.1.10.4 Eligibility Criteria

<a id="topic-3.1.10.4-1"></a>

#### Participant type and age in the EU register

| Field | Register entry |
| --- | --- |
| Medical condition | “Medical condition(s) Healthy female participants of childbearing potential.” |
| Participants type | “Participants type Healthy volunteers” |
| Age range | “Age range 18-64 years” |

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00)

<a id="heading-3.1.10.5"></a>

### 3.1.10.5 Treatment

<a id="topic-3.1.10.5-1"></a>

#### Multiple doses of obefazimod with ethinyl estradiol and drospirenone

> “multiple doses of obefazimod on a combined oral contraceptive (ethinyl estradiol/drospirenone)”

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00)

<a id="heading-3.1.10.6"></a>

### 3.1.10.6 Study Outcomes

<a id="heading-3.1.10.6.1"></a>

#### 3.1.10.6.1 Rationale for Using Combined Oral Contraceptive Pharmacokinetics as the Study Endpoint

No evidence found.

<a id="heading-3.1.10.7"></a>

### 3.1.10.7 Statistical Analysis Description

<a id="heading-3.1.10.7.1"></a>

#### 3.1.10.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.10.7.1-1"></a>

##### Planned participants in the EU register

> “Belgium: Ended. Planned participants: 36”

Source: [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00)

<a id="topic-3.1.10.7.1-2"></a>

##### Enrollment in the two drug-drug interaction trials stated in the Form 20-F

> “for which we enrolled 24 and 36 healthy volunteers respectively”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.10.7.2"></a>

#### 3.1.10.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.10.8"></a>

### 3.1.10.8 Results

<a id="heading-3.1.10.8.1"></a>

#### 3.1.10.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.10.8.2"></a>

#### 3.1.10.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.10.8.3"></a>

#### 3.1.10.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.10.8.4"></a>

#### 3.1.10.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.10.8.5"></a>

#### 3.1.10.8.5 Safety Results

No evidence found.

<a id="heading-3.1.10.9"></a>

### 3.1.10.9 Study Limitations

<a id="topic-3.1.10.9-1"></a>

#### Summary

ABX464-910 has only an EU register record and a sentence in the Form 20-F, which does not name the trial by protocol number. The register gives the title, the dates (10 October 2023 to 31 August 2024), one site in Belgium, and 36 planned healthy women of childbearing potential aged 18 to 64 years. The doses, sampling schedule, endpoints, and the hormone measured are not public, and the summary of results is deferred until 28 February 2027. The 20-F states that the two drug-drug interaction trials were completed in 2025, whereas the register gives 31 August 2024 as the end of this trial. No pharmacokinetic or safety result has been published, so the effect of obefazimod on contraceptive exposure is unknown from public sources.

Source: [EU Clinical Trials Information System 2023-505297-15-00](https://euclinicaltrials.eu/ctis-public/view/2023-505297-15-00); [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.10.9-2"></a>

#### Results publication deferred in the EU register

> “Summary of the results: deferred: adult category 1 trial (mostly phase I), results to be published from 28 Feb 2027 (EMA/263067/2023).”

Source: [CTIS.eu 2023-505297-15-00](https://ctis.eu/trial/2023-505297-15-00)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
